Chemours Co (CC) stock
CCNYSEChemicals & Allied ProductsFiscal year ends December 31
$13.35−0.37 (-2.70%)
Close on Nov 12, 2026Market cap $2.01BP/E –Yield 3.84%
Chemours EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Chemours's EPS for the twelve months ending Sep 30, 2026 was -$1.02. For fiscal 2025 it was -$2.57, down 658.7% from the year before. The highest annual figure on record is $5.45 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.57 | -658.7% |
| FY2024 | Dec 31, 2024 | $0.46 | – |
| FY2023 | Dec 31, 2023 | -$1.70 | -146.6% |
| FY2022 | Dec 31, 2022 | $3.65 | +1.4% |
| FY2021 | Dec 31, 2021 | $3.60 | +172.7% |
| FY2020 | Dec 31, 2020 | $1.32 | – |
| FY2019 | Dec 31, 2019 | -$0.32 | -105.9% |
| FY2018 | Dec 31, 2018 | $5.45 | +39.4% |
| FY2017 | Dec 31, 2017 | $3.91 | +9675.0% |
| FY2016 | Dec 31, 2016 | $0.04 | – |
| FY2015 | Dec 31, 2015 | -$0.50 | -122.6% |
| FY2014 | Dec 31, 2014 | $2.21 | -5.6% |
| FY2013 | Dec 31, 2013 | $2.34 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.29 | +316.1% |
| Q2 FY2026 | Jun 30, 2026 | -$1.81 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.19 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.31 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.31 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.53 | -748.7% |
| Q1 FY2025 | Mar 31, 2025 | -$0.03 | -108.3% |
| Q4 FY2024 | Dec 31, 2024 | -$0.08 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.22 | -375.0% |
| Q2 FY2024 | Jun 30, 2024 | $0.39 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.36 | -62.5% |
| Q4 FY2023 | Dec 31, 2023 | -$0.12 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.08 | -94.7% |
| Q2 FY2023 | Jun 30, 2023 | -$2.52 | -300.0% |
| Q1 FY2023 | Mar 31, 2023 | $0.96 | -32.9% |
| Q4 FY2022 | Dec 31, 2022 | -$0.65 | -146.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.52 | +19.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.26 | +223.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.43 | +150.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.40 | +1172.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.27 | +176.1% |
| Q2 FY2021 | Jun 30, 2021 | $0.39 | +160.0% |
| Q1 FY2021 | Mar 31, 2021 | $0.57 | -6.6% |
| Q4 FY2020 | Dec 31, 2020 | $0.11 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.46 | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.15 | -73.7% |
| Q1 FY2020 | Mar 31, 2020 | $0.61 | +10.9% |
| Q4 FY2019 | Dec 31, 2019 | -$1.94 | -339.5% |
| Q3 FY2019 | Sep 30, 2019 | $0.46 | -69.5% |
| Q2 FY2019 | Jun 30, 2019 | $0.57 | -62.7% |
| Q1 FY2019 | Mar 31, 2019 | $0.55 | -65.2% |
| Q4 FY2018 | Dec 31, 2018 | $0.81 | -31.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.51 | +39.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.53 | +82.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.58 | +100.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.19 | – |
| Q3 FY2017 | Sep 30, 2017 | $1.08 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.84 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.79 | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.26 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?